Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of investigational drugs, pembrolizumab alone or
pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given
before and after surgery to remove kidney cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania